Corpus ID: 1482184

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

@article{Russo2008ClinicalED,
  title={Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?},
  author={Ethan B. Russo},
  journal={Neuro endocrinology letters},
  year={2008},
  volume={29 2},
  pages={
          192-200
        }
}
  • Ethan B. Russo
  • Published 1 April 2008
  • Medicine
  • Neuro endocrinology letters
OBJECTIVES This study examines the concept of clinical endocannabinoid deficiency (CECD), and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis. [...] Key MethodMETHODS Available literature was reviewed, and literature searches pursued via the National Library of Medicine database and other resources. RESULTS Migraine has numerous relationships to endocannabinoid function. Anandamide…Expand
Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
TLDR
Subsequent research has confirmed that underlying endocannabinoid deficiencies indeed play a role in migraine, fibromyalgia, irritable bowel syndrome and a growing list of other medical conditions. Expand
Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes
TLDR
This theory was based on genetic overlap and comorbidity, patterns of symptomatology that could be mediated by the endocannabinoid system (ECS), and the fact that exogenous cannabinoid treatment frequently provided symptomatic benefit, but objective proof and formal clinical trial data were lacking. Expand
Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System
TLDR
Evidence indicates that several classes of pharmaceuticals upregulate the eCB system, including analgesics, non-steroidal anti-inflammatory drugs, opioids, glucocorticoids, antidepressants, antipsychotics, anxiolytics, and anticonvulsants. Expand
Phytomedicines in the Treatment of Migraine
TLDR
The evidence for feverfew is mixed; butterbur is effective with potential risks of hepatotoxicity related to preparation; marijuana has not been shown to be effective in migraine treatment, and data are scant; Saint John’s Wort shows relevant physiological activity but is a hepatic enzyme inducer and lacks clinical studies for this purpose; the Damask rose when used in topical preparations did not show efficacy in one clinical trial. Expand
Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice
TLDR
It is found that nitroglycerin-induced mechanical allodynia and neuronal activation of the trigeminal nucleus were completely abolished in FAAH-deficient mice, identifying FAAH as a target for migraine pharmacotherapy. Expand
A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol.
TLDR
The hypothesis that the combination of THC and CBD increases clinical efficacy while reducing adverse events is supported, and prospects for future application of whole cannabis extracts in neuroprotection, drug dependency, and neoplastic disorders are examined. Expand
Cannabis Use in Fibromyalgia
Fibromyalgia is a chronic disorder characterized by widespread pain and tenderness, often accompanied by fatigue, memory problems, and sleep disturbances. Therapy includes both nonpharmacologicalExpand
Cannabis Therapeutics and the Future of Neurology
TLDR
The inherent polypharmaceutical properties of cannabis botanicals offer distinct advantages over the current single-target pharmaceutical model and portend to revolutionize neurological treatment into a new reality of effective interventional and even preventative treatment. Expand
Cannabis for Pain and Headaches: Primer
TLDR
Phytocannabinoids have been identified as key compounds involved in analgesia and anti-inflammatory effects and other compounds found in cannabis such as flavonoids and terpenes are also being investigated as to their individual or synergistic effects. Expand
Irritable Bowel Syndrome: Manipulating the Endocannabinoid System as First-Line Treatment
TLDR
The Endocannabinoid System (ECS) is known to modulate several functions, including mood, anxiety, and memory retrieval of traumatic events and it directly coordinates GI propulsion, secretion, inflammation, and nociception, providing a rationale for agents capable of interacting with the ECS as treatment candidates for IBS. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 164 REFERENCES
Cannabinoids and Cystic Fibrosis: A Novel Approach to Etiology and Therapy
TLDR
It is proposed here for the first time, to administer THC to Cystic Fibrosis patients, hoping that the cannabinoid will alleviate malnutrition and thus help prevent wasting in CF patients and by elevating these levels, symptoms may improve. Expand
Cannabinoids for gastrointestinal diseases: potential therapeutic applications
  • G. Carlo, A. Izzo
  • Chemistry, Medicine
  • Expert opinion on investigational drugs
  • 2003
TLDR
A pharmacological modulation of the endogenous cannabinoid system could provide new therapeutics for the treatment of a number of gastrointestinal diseases, including nausea and vomiting, gastric ulcers, irritable bowel syndrome, Crohn’s disease, secretory diarrhoea, paralytic ileus and gastroesophageal reflux disease. Expand
Negative modultors of excitatory amino acids in episodic and chronic migraine: preventing and reverting chronic migraine. Special lecture 7th INWIN Congress.
The mechanism capable of transforming episodic migraine into chronic migraine is attributed by the authors to hyperalgesia and related neuroplastic changes, chiefly long-term potentiation, due to theExpand
Cannabinoids control spasticity and tremor in a multiple sclerosis model
TLDR
It is shown that cannabinoid (CB) receptor agonism quantitatively ameliorated both tremor and spasticity in diseased mice, providing a rationale for patients' indications of the therapeutic potential of cannabis in the control of the symptoms of multiple sclerosis. Expand
Fibromyalgia and headache. Failure of serotonergic analgesia and N-methyl-D-aspartate-mediated neuronal plasticity: their common clues.
TLDR
Empirical data is analysed supporting the hypothesis that analgesic disruption and a consequent hyperalgesic state are mechanisms of both migraine and fibromyalgia and suggest that migraine may represent a risk factor for fibromy arthritis. Expand
Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy.
TLDR
The combination of MAOIs with 5-HTP significantly improved fibromyalgia syndrome as determined by Visual Analogic Scale whereas the other treatments yielded poorer benefits. Expand
Evaluation of drug treatment in irritable bowel syndrome.
  • N. Talley
  • Medicine
  • British journal of clinical pharmacology
  • 2003
TLDR
A meta-analysis concluded that the tricyclic antidepressants were superior to placebo in IBS, although the individual trial results were variable, and additional efficacious therapeutic options for patients with IBS will soon emerge. Expand
The Pharmacology of Current Anti‐Migraine Drugs
TLDR
It is found that acute anti-migraine agents (e.g., ergots, sumatriptan) share high affinity for 5-HT1D receptors, which appears to be present in certain intracranial blood vessels and may mediate neuronal depolarizations at the cellular level. Expand
Cannabinoids in pain management
  • E. Russo
  • Medicine
  • BMJ : British Medical Journal
  • 2001
TLDR
The authors chose to broaden the alleged impact of their limited investigation to relegate the use of cannabis and cannabinoids to a back seat in future analgesic applications, and this contention is not supported by their limited data. Expand
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
TLDR
Treatment with cannabinoids did not have a beneficial effect on spasticity when assessed with the Ashworth scale, but objective improvement in mobility and patients' opinion of an improvement in pain suggest cannabinoids might be clinically useful. Expand
...
1
2
3
4
5
...